STOCK TITAN

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
earnings date

CollPlant Biotechnologies (Nasdaq: CLGN) announced it will report third quarter 2025 financial results on Wednesday, November 26, 2025, before the U.S. market open. The company develops non-animal-derived rhCollagen products for tissue regeneration and medical aesthetics. Investors can expect the company to release results and any accompanying commentary or materials on that date.

Loading...
Loading translation...
Argus Nov 18 session
+0.94% close to close 0.5x rel. volume Open Argus
Details

News Market Reaction – CLGN

On Nov 18, the day this news came out, CLGN closed 0.94% above the previous close.

Data tracked by StockTitan Argus for the Nov 18 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

REHOVOT, Israel, Nov. 18, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 26, 2025, before the opening of the U.S. financial markets.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.

For more information about CollPlant, visit http://www.collplant.com

Contacts

CollPlant:
Eran Rotem   
Deputy CEO & CFO
Tel: +972-73-2325600
Email: eran@collplant.com  

Investors:
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com 

Cision View original content:https://www.prnewswire.com/news-releases/collplant-biotechnologies-announces-date-for-2025-third-quarter-financial-results-302618450.html

SOURCE CollPlant

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will CollPlant (CLGN) report Q3 2025 results?

CollPlant will report Q3 2025 results on November 26, 2025, before the U.S. market opens.

What time will CollPlant (CLGN) release its November 26, 2025 results?

The company said results will be released before the U.S. market open on November 26, 2025.

How can investors access CollPlant (CLGN) Q3 2025 financial results?

Investors should check CollPlant investor relations and Nasdaq filings on November 26, 2025 for the full release.

Will CollPlant (CLGN) provide a conference call with the Q3 2025 results?

The announcement only scheduled the results release for November 26, 2025; any call or webcast was not specified.

What does CollPlant (CLGN) make and how is it described in the announcement?

CollPlant develops non-animal-derived rhCollagen technologies and products for tissue regeneration and medical aesthetics.

Keep reading